Eyelids are very complex structure, reconstruction of which is a challenge to surgeons. Reconstruction of eyelids may be required in a variety of conditions like congenital anomalies, trauma, or postsurgical excision in malignant lesions involving the eyelids. There are numerous ways to reconstruct the eyelids; the best procedure depends on both the skill of the surgeon and the condition of the patient. Fricke' lateral temporal based flap was first described in 1829 for reconstruction of the eyelids and lateral canthal region. This flap had inherent problems regarding cosmetic appearance of the eyebrows. The modified Fricke's flap based on the cheek has the advantage of avoiding such complications. It is very easy and rapid outpatient department (OPD) based procedure with acceptable cosmetic and functional result. It can be done by all ear, nose, and throat (ENT) and head and neck surgeons without any reconstructive training. In this article we are presenting a case of total reconstruction of lower eyelid using the modified Fricke's cheek flap.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3977334 | PMC |
| http://dx.doi.org/10.4103/2006-8808.128749 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Development of KoRV-pseudotyped lentiviral vectors for efficient gene transfer into freshly isolated immune cells.
Gene Ther
July 2024
Fraunhofer Institute for Cell Therapy and Immunology (IZI), Department for Cell and Gene Therapy Development, Leipzig, Germany.
Article Synopsis
- Allogeneic cell therapies, particularly those using NK cells and macrophages, face challenges in genetic modification due to inefficiencies in current viral vector techniques.
- The study introduces a new lentiviral pseudotype using the Koala Retrovirus envelope, which efficiently transduces freshly isolated human NK cells and monocytes with up to 80% gene expression without compromising cell functionality.
- This innovation streamlines the production of cell-based therapeutics, making it quicker and less resource-intensive, which could lead to faster patient access to effective cancer treatments.
CAR T cells for treating autoimmune diseases.
RMD Open
November 2023
Fraunhofer Institute for Cell Therapy and Immunology IZI, Leipzig, Germany.
Autoimmune disorders occur when immune cells go wrong and attack the body's own tissues. Currently, autoimmune disorders are largely treated by broad immunosuppressive agents and blocking antibodies, which can manage the diseases but often are not curative. Thus, there is an urgent need for advanced therapies for patients suffering from severe and refractory autoimmune diseases, and researchers have considered cell therapy as potentially curative approach for several decades.
View Article and Find Full Text PDFComparison of two lab-scale protocols for enhanced mRNA-based CAR-T cell generation and functionality.
Sci Rep
October 2023
Department for Cell and Gene Therapy Development, Fraunhofer Institute for Cell Therapy and Immunology (IZI), Perlickstr. 1, 04103, Leipzig, Germany.
Process development for transferring lab-scale research workflows to automated manufacturing procedures is critical for chimeric antigen receptor (CAR)-T cell therapies. Therefore, the key factor for cell viability, expansion, modification, and functionality is the optimal combination of medium and T cell activator as well as their regulatory compliance for later manufacturing under Good Manufacturing Practice (GMP). In this study, we compared two protocols for CAR-mRNA-modified T cell generation using our current lab-scale process, analyzed all mentioned parameters, and evaluated the protocols' potential for upscaling and process development of mRNA-based CAR-T cell therapies.
View Article and Find Full Text PDFDetection of Immune Checkpoint Receptors - A Current Challenge in Clinical Flow Cytometry.
Front Immunol
December 2021
Institute of Clinical Immunology, Medical Faculty, University of Leipzig, Leipzig, Germany.
Immunological therapy principles are increasingly determining modern medicine. They are used to treat diseases of the immune system, for tumors, but also for infections, neurological diseases, and many others. Most of these therapies base on antibodies, but small molecules, soluble receptors or cells and modified cells are also used.
View Article and Find Full Text PDF[Replacement of the lower eyelid after tumor removal].
Orv Hetil
July 2021
1 Debreceni Egyetem, Kenézy Gyula Egyetemi Kórház, Szemészeti Osztály, Debrecen, Bartók Béla u. 2-26., 4031.
Unlabelled: Összefoglaló. Bevezetés: A tumoreltávolítás miatt végzett teljes alsószemhéj-pótlás összetett feladat lehet. A rekonstrukció célja a kielégítő funkcionális és kozmetikai eredmény elérése.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!